In 84,246 consecutive Italians tested for SARS-CoV-2, we examined the prevalence of cancer and clinical outcomes of viral infection. Overall, 5.7% (4,789/84,246) had previously been diagnosed with cancer and, among the SARS-CoV-2-positive (CV2+ve) patients, 7.8% had a cancer diagnosis (723/9,275). Prevalence of cancer was not associated with risk of infection (odds ratio of 0.97; 95% confidence interval of 0.89–1.06). The proportion of CV2+ve people hospitalized was higher among patients with cancer (56.6 versus 34.4% among other people), and so was the proportion of deaths (14.7% versus 4.5%). The risk of adverse outcomes of SARS-CoV-2 infection was significantly higher for patients with cancer versus those without, particularly for males and older people.

在连续 84,246 名意大利人中进行了 SARS-CoV-2 检测，我们检查了癌症的患病率和病毒感染的临床结果。总体而言，5.7% (4,789/84,246) 曾被诊断出患有癌症，在 SARS-CoV-2 阳性 (CV2+ve) 患者中，7.8% 被诊断出患有癌症 (723/9,275)。癌症患病率与感染风险无关（优势比为 0.97；95% 置信区间为 0.89-1.06）。癌症患者中 CV2+ve 住院患者的比例较高（56.6% vs 34.4%），死亡比例也较高（14.7% vs 4.5%）。癌症患者发生 SARS-CoV-2 感染不良后果的风险明显高于非癌症患者，尤其是男性和老年人。